BSXBoston Scientific
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. 10-K, Item 1
- Employees
- 59,000
- Headquarters
- Marlborough, MA
- CEO
- Michael F. Mahoney
- Next results
- around Feb 3, 2027
What changed
10-K filed Feb 17, 2026 against Feb 18, 2025| Area | What changed | Source |
|---|---|---|
| Risk factors | 3 new paragraphs, nothing like them in the previous 10-K | 10-K Item 1A |
| Critical audit matters changed | New this year: Valuation of intangible assets acquired in business combinations (“As disclosed in Note B to the consolidated financial statements, during 2025, the Company completed the acquisitions of Bolt Medical, Inc. and SoniVie Ltd. for purchase prices, net of cash acquired, of $782 million and $516 million, respectively.”) | 10-K · XBRL |
| Accounting checks | 10 other checks clear, 1 worth a look | 10-K · XBRL |
| Insiders | 1 open-market buy in the last 90 days | Form 4 |
| Filings | 2 in the last 30 days | EDGAR |
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
What's new, in their words
10-K filed Feb 17, 2026Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-18. Quoted as filed.
Our business and operations are subject to risks related to natural disasters, climate change and other extreme weather.
10-K, Item 1A
Accounting checks
latest 10-K10 of 11 clear 1 worth a look. Checks, not verdicts.
- !Critical audit matters changedNew this year: Valuation of intangible assets acquired in business combinations (“As disclosed in Note B to the consolidated financial statements, during 2025, the Company completed the acquisitions of Bolt Medical, Inc. and SoniVie Ltd. for purchase prices, net of cash acquired, of $782 million and $516 million, respectively.”)
- ✓Receivables +14.4% vs revenue +19.9% (-5.5 pts)
- ✓Cash from operations $4.5B vs net income $2.9B (FY ending 2025-12-31)
- ✓Inventory +4.7% vs revenue +19.9% (-15.1 pts)
- ✓Same auditor in both 10-Ks: Ernst & Young LLP
- ✓No statement of substantial doubt about going concern
- ✓No 8-K item 4.02 in the last 2 years
- ✓No NT 10-K or NT 10-Q in the last 2 years
- ✓No sentence in the 10-K concludes that controls were not effective because of a material weakness
- ✓No 8-K item 2.06 in the last 2 years
- ✓No 8-K item 1.03 in the last 2 years
In the last 30 days
All filings →- Nov 2, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026
- Oct 28, 20268-K Quarterly results 8-K item 2.02
Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q.
RSS feed
Work on BSX in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/BSX/export.csv") into a cell.